EBV-specific anti-PD1 TCR-T cells / TCRCure - LARVOL DELTA

EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: Xinqiao Hospital of Chongqing | Suspended ➔ Recruiting

Enrollment open • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • IL2

EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma (clinicaltrials.gov) - P1/2 | N=20 | Recruiting | Sponsor: Xinqiao Hospital of Chongqing | Suspended ➔ Recruiting

Enrollment open • Metastases • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC (clinicaltrials.gov) - P1/2 | N=18 | Suspended | Sponsor: Xinqiao Hospital of Chongqing | Trial completion date: Jan 2024 ➔ Dec 2024 | Recruiting ➔ Suspended | Trial primary completion date: Jan 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Trial suspension • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • IL2

EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma (clinicaltrials.gov) - P1/2 | N=20 | Suspended | Sponsor: Xinqiao Hospital of Chongqing | Trial completion date: Aug 2023 ➔ Dec 2024 | Recruiting ➔ Suspended | Trial primary completion date: Aug 2023 ➔ Dec 2024

Metastases • Trial completion date • Trial primary completion date • Trial suspension • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial. (ASCO 2023) - P1/2 | "Fludarabine/cyclophosphamide were administered prior to TCR-T cell transfer as pre-conditioning... EBV-targeting TCR-T cells armored with PD-1 blockade are well tolerated. Initial results from this ongoing study indicate that EBV proteins may be safe and effective TCR-T targets to achieve superior outcomes in advanced EBV-positive NPC patients. Clinical trial information: NCT04139057."

Checkpoint block • Checkpoint inhibition • P1/2 data • Epstein-Barr Virus Infections • Hematological Disorders • Immune Modulation • Leukopenia • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • HLA-A • IL2 • PD-L1

EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma (clinicaltrials.gov) - P1/2 | N=20 | Recruiting | Sponsor: Xinqiao Hospital of Chongqing | Not yet recruiting ➔ Recruiting | Trial primary completion date: Aug 2021 ➔ Aug 2023

Enrollment open • Metastases • Trial primary completion date • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: Xinqiao Hospital of Chongqing | Trial completion date: Feb 2022 ➔ Jan 2024 | Trial primary completion date: Feb 2022 ➔ Jan 2024

Trial completion date • Trial primary completion date • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • IL2